National Cancer Institute

U.S. National Institutes of Health | www.cancer.gov

Introduction

OMB #0000-0000-00 Exp. Date: 00/00/0000

The National Cancer Institute (NCI) and the [COOP GROUP NAME] have developed a **brief online survey** tool to quickly and easily solicit comments from oncologists and research staff in the field about specific NCI clinical **trials that have low accrual rates**.

We would like your opinions about the [TRIAL NAME] ([TRIAL DESCRIPTION]).

Your comments will help NCI and the [COOP GROUP NAME] to decide how to move forward with the [TRIAL NAME] trial and possible ways to increase its accrual and reach its projected goals. We thank you for your assistance!

To continue and begin the survey, click the "Next" button below.

Next -->

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

National Cancer Institute

U.S. National Institutes of Health | www.cancer.gov

Privacy Statement and Consent

Your participation in this survey is completely voluntary. Please be assured that your participation in the survey is anonymous and your responses cannot be linked or associated with you.

You may skip any questions that you prefer not to answer. You are also free to stop participating at any point during the survey and have your responses deleted by clicking the "Opt out of survey" box at the bottom of each survey page.

This brief survey should only require approximately 5 minutes of your time.

Please click the "Next" button if you consent to taking this survey.

Opt out of survey

Next -->

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and meintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 208927974, ATTN: PRA (0000-0000-00). Do not return the completed form to this address.

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com



National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Please reply to all questions from the perspective of your site.	
Please indicate which best describes your site:	
 My practice is located within an academic medical center 	
 My practice is located within an NCI-Designated Cancer Cent 	ter
 My practice is located within a community hospital (i.e., non-a 	cademic, medical center hospitals)
 I/We are a free-standing private practice 	
Other:	
1a. What best describes the size of your community hospital com	pared to others?
We are a small-size community hospital (less than 100 bed	ds)
 We are a mid-size community hospital (between 100-250 b 	
 We are a large-size community hospital (more than 250 be 	ds)
Please indicate which best describes your site's affiliation(s): (Ple	ease check all that apply)
CCOP	
MB-CCOP	
NCCCP	
□ ALLIANCE	
□ ECOG-ACRIN	
□ SWOG	
□ RTOG-NSABP-GOG	
□ COG	
□ EORTC	
□ COGNO (Cancer Australia)	
□ NCIC	
☐ Other:	
Which category best describes your role at your practice?	
Physician	
Physician Staff member/other	
O Stall Member/other	
Opt out of survey	Save and Continue>
If you experience any technical difficulties, please conta at User-Centered Design at survey@user-cen	

Note: Q1a appears only if "My practice is located within a community hospital" is selected for Q1.

If user selects "physician" to Q3, continue below. If user selects "Staff member/other", continue <u>HERE</u>.

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
What type of oncology best describes your expertise?	
Medical oncology	
 Surgical oncology 	
 Radiation oncology 	
 Gynecologic oncology 	
 Pediatric oncology 	
○ [VARIABLE]	
Other:	
Opt out of survey	Save and Continue>
If you experience any technical difficulties, plea: at User-Centered Design at <u>survey@</u>	


The state of the s	ancer Institu	ute		U.S. National Institutes of Health www.cancer.g
e ITRIAL NAME	trial has [INSER	RT #1 research	question(s) (F	or each,] Please tell us how scientifically
esting it is to you.	arar rao (ii voer	(T m) roodardir	quoscori[o]. [r	or each of reason as now economically
Q1: [INSERT RQ1	FROM CONC	EPT SHEET]		
5a1. How scientif	fically interestin	g is this resear	rch question to	you?
Not at all interesting				Very interesting
0	0	0	0	0
5a2. Which state	ment best match	hes your opinio	on?	
○ RQ1 is more	interesting to m	e than when it	first opened.	
RQ1 is less in	nteresting to me	than when it fi	rst opened.	
RQ1 is about	the same level	interest to me	as when it firs	t opened.
Please elaborate	ı:			
,				
,				
02: (INSERT RO	FROM CONC	EPT SHEETI		
Q2: [INSERT RQ2	FROM CONC	EPT SHEET]		
22: [INSERT RQ2			rch question to	o you?
5b1. How scientif			rch question to	Very
5b1. How scientif			rch question to	
5b1. How scientif			rch question to	Very
5b1. How scientification Not at all interesting	fically interestin	g is this resear	0	Very interesting
5b1. How scientification Not at all interesting 5b2. Which states	fically interestin	ng is this resear	on?	Very interesting
5b1. How scientification Not at all interesting 5b2. Which state	fically interesting ment best matchineresting to m	ng is this resear	on?	Very interesting
5b1. How scientification Not at all interesting 5b2. Which states RQ2 is more in RQ2 is less in	ment best match	ng is this resear hes your opinion than when it is	on? first opened.	Very interesting
5b1. How scientification Not at all interesting 5b2. Which states RQ2 is more in RQ2 is less in RQ2 is about	ment best match interesting to me the same level	ng is this resear hes your opinion than when it is	on? first opened.	Very interesting
5b1. How scientification Not at all interesting 5b2. Which states RQ2 is more in RQ2 is less in	ment best match interesting to me the same level	ng is this resear hes your opinion than when it is	on? first opened.	Very interesting
5b1. How scientification Not at all interesting 5b2. Which states RQ2 is more in RQ2 is less in RQ2 is about	ment best match interesting to me the same level	ng is this resear hes your opinion than when it is	on? first opened.	Very interesting
5b1. How scientification Not at all interesting 5b2. Which states RQ2 is more in RQ2 is less in RQ2 is about	ment best match interesting to me the same level	ng is this resear hes your opinion than when it is	on? first opened.	Very interesting
5b1. How scientification Not at all interesting 5b2. Which states RQ2 is more in RQ2 is less in RQ2 is about	ment best match interesting to me the same level	ng is this resear hes your opinion than when it is	on? first opened.	Very interesting
5b1. How scientification Not at all interesting 5b2. Which states RQ2 is more in RQ2 is less in RQ2 is about	ment best match interesting to me the same level	ng is this resear hes your opinion than when it is	on? first opened.	Very interesting

松絲 National	Cancer In	stitute		U.S. National Institu	tes of Health www.cancer.gov
6. Assuming the [Tri on your treatment o			as planned, w	hat impact do you beli	eve the findings will have
Limited impact				High impact	
0	0	0	0	0	
7. How much do yo	u agree or disa	agree with this s	tatement?		
The potential be conduct it at my		trial for patient	s are worth th	e effort and resource	es required to open and
Strongly Disagree				Strongly Agree	
0	0	0	0	0	
8. If you had the op accrual? Please be	as specific as				AME] trial with respect to

For each of the trial's requirements listed below, please te open or run the [TRIAL NAME] trial at your site.	II us whether o	or not it does	(or would) ma	ake it difficu
How difficult does (or would) this requirement make run this trial at your site?	it to open or	Not make it difficult to open/ run the trial	Make it somewhat difficult to open/ run the trial	Make it yery difficult to open/run the trial
[INSERT ITEM 1 FROM TRIAL SUMMARY SHEET]		0	0	0
[INSERT ITEM 2 FROM TRIAL SUMMARY SHEET]	,	0	0	0
[INSERT ITEM 3 FROM TRIAL SUMMARY SHEET]		0	0	0
[INSERT ITEM N FROM TRIAL SUMMARY SHEET]		0	0	0

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
10. How often do you see a patient who may be eligible	for the [TRIAL NAME] trial (i.e., [PATIENT TYPE])?
○ Daily	
Weekly	
Monthly	
Every few months	
A couple times per year or less	
11. Which specialty at your institution would most likely potentially eligible patient?	be in the position to recommend or refer this trial to a
Medical oncology	
 Surgical oncology 	
 Radiation oncology 	
 Gynecologic oncology 	
 Pediatric oncology 	
○ [VARIABLE]	
Other (please specify):	
Opt out of survey	Save and Continue>
	es, please contact the survey administrator urvey@user-centereddesign.com

How difficult does (or would) this issue make it to accrue patients to this trial?	Not make it difficult to accrue patients to the trial	Make it somewhat difficult to accrue patients to the trial	Make it very difficult to accrue patients to the trial
Burden on patient to participate in the trial (e.g., logistics, time)	0	0	0
Inclusion/exclusion criteria of the study	0	0	0
Patients declining to enroll (e.g., unwilling to randomize, prefer one study arm)	0	0	0
Explaining the trial's details to a patient, including consenting	0	0	0
Getting patients referred to the trial	0	0	0
Cost to the patient (e.g., insurance, reimbursement)	0	0	0
lease elaborate – or provide additional reasons – why you believe th atients at your site:	is trial might b	e difficult to a	ccrue



If user selects "Yes" to Q14, continue below. If user selects "No", continue HERE.

20 (10 (000) 000)	Cancer Ins	stitute		U.S. National Institute	es of Health www.cancer.gov
5. To date, how man	ny patients ha	as your site accr	rued to the [TR	IAL NAME] trial?	
(Number of pa	atients - integ	gers only)			
☐ My site has not	opened this	trial.			
6. How difficult was	the [TRIAL N	IAME] trial to op	en at your site	?	
Not at all difficult				Very difficult	
0	0	0	0	0	
Why?					
	the study (e.g imbursable e terest by onc iteresting res study drug(s) g trials for this ed for our cur on patient (e	p., limited burder expenses cologist(s) in the earch question(s cancer rent patient pop	n on staff or coo	al at your site? [Select	
Other:					

Nationa	al Cancer Institute	U.S. National Institutes of Health www.cancer.gov				
18. Do you have a	18. Do you have any final comments about the [TRIAL NAME] trial that you would like to share?					
		12 55				
45						
Opt out of survey		Submit Survey>				
	If you experience any technical difficulties, p at User-Centered Design at survey					

	National	Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Survey Co	omplete		
		Thank you for co	empleting this survey!
		Your answers have be	en submitted anonymously.
Y	our comme		regarding the [TRIAL NAME] trial. ve forward to address the trial's accrual challenges.
	If you wo		after the survey closes, please send an email to ab@mail.nih.gov
		You may now	close this window.
			lties, please contact the survey administrator survey@user-centereddesign.com

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
13. How many similar trials are open at your site that compete f NAME] trial?	or the same patient population as the [TRIAL
Number of similar trials open at you (Integers on	
# competing trials that are sponsored by NCI (including	cooperative group trials)
# competing trials that are sponsored by pharmaceutic	al/biotech industry
# competing trials that are investigator initiated trials fro	om academic medical centers
14. Has your site opened the [TRIAL NAME] trial? Yes No	Save and Continue>
If you experience any technical difficulties, please at User-Centered Design at <u>survey@us</u>	


<u>網</u> National	Cancer Ins	stitute		U.S. National Institut	tes of Health www.cancer.gov
5. Given what you our site?	read in the tria	al summary shee	et, how interes	ted are you in opening	the [TRIAL NAME] trial at
Not at all interested				Very interested	
0	0	0	0	0	
Financial cost to	eting trials for urden on patie onduct the stud our site would corue patients	this cancer nts (e.g., logistic dy (e.g., burden d be too great (e (e.g., randomiza	on staff, coord	ination required, equip ursable expenses) g many to identify one;	ment needed) ; anticipate high refusals)
Opt out of survey					Save and Continue
				contact the survey administra r-centereddesign.com	tor

Nationa	l Cancer Institute	U.S. National Institutes of Health www.cancer.gov
17. Do you have ar	ny final comments about the [TRIAL NAME] trial	that you would like to share?
Opt out of survey		Submit Survey>
	If you experience any technical difficulties, please conta at User-Centered Design at survey@user-cen	

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Survey Complete	
Thank you for complete	ing this survey!
Your answers have been sub	omitted anonymously.
We appreciate your feedback regard Your comments will help us decide how to move forw	
If you would like a summary of the findings after the 61164thflrlab@ma	
You may now close	this window.
If you experience any technical difficulties, ple at User-Centered Design at <u>survey@</u>	

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Please reply to all questions from the perspective of <u>your</u> site.	
Please indicate which best describes your site:	
My practice is located within an academic medical center	er .
My practice is located within an NCI-Designated Cancer	
 My practice is located within a community hospital (i.e., r 	
I/We are a free-standing private practice	
Other:	
1a. What best describes the size of your community hospital	compared to others?
 We are a small-size community hospital (less than 10 	0 beds)
 We are a mid-size community hospital (between 100- 	
 We are a large-size community hospital (more than 25) 	
Please indicate which best describes your site's affiliation(s)	: (Please check all that apply)
CCOP	
□ MB-CCOP	
□ NCCCP	
□ ALLIANCE	
□ ECOG-ACRIN	
□ SWOG	
☐ RTOG-NSABP-GOG	
□ COG	
□ EORTC	
□ COGNO (Cancer Australia)	
□ NCIC	
Other:	
Which category best describes your role at your practice?	
Physician	
Staff member/other	
Opt out of survey	Save and Continue>
If you experience any technical difficulties, please at User-Centered Design at survey@us	


Note: Q1a appears only if "My practice is located within a community hospital" is selected for Q1.



	Cancer Ins	stitute		U.S. N	National Institut	tes of Health w	ww.cancer.gov
tients have been a ch, NCI and [COO	ccrued to the tria	by the [COOP GRO al. We expected a si ME] are interested in e its accrual and rea	ignificantly mo learning from	re robust a the field wh	ccrual than v	we have experi	enced. As
. How much do y	ou agree or dis	sagree with this sta	atement?				
The potential be		trial for patients a	are worth the	effort an	d resource	es required to	open and
Strongly Disagree				Strong			
0	0	0	0	0			
. For each of the	trial's requirem	nents listed below, NAME] trial at your	please tell us	s whether	or not it doe	es (or would) r	make it
. For each of the ficult to open or r	trial's requirem un the [TRIAL N	nents listed below,	please tell us r site.		Not make it difficult to open/run the trial	Make it somewhat difficult to open/run the trial	Make it yery difficult to open/run the trial
For each of the ficult to open or r	trial's requirem un the [TRIAL N oes (or would run this t	nents listed below, NAME] trial at your	please tell us r site. t make it to o		Not make it difficult to open/ run	Make it somewhat difficult to open/ run	Make it yery difficult to open/run
For each of the ficult to open or r	trial's requirem un the [TRIAL N oes (or would run this t	nents listed below, NAME] trial at your) this requirementrial at your site?	please tell us r site. t make it to d		Not make it difficult to open/ run the trial	Make it somewhat difficult to open/ run the trial	Make it yery difficult to open/run the trial
For each of the ficult to open or r	trial's requirem un the [TRIAL for the content of t	nents listed below, NAME] trial at your) this requirementrial at your site?	please tell us r site. t make it to o		Not make it difficult to open/ run the trial	Make it somewhat difficult to open/run the trial	Make it yery difficult to open/run the trial

National	Cancer Ins	stitute		U.S. National Institut	es of Health www.cancer.gov
S4. How often does y TYPE])?	your practice	see patients wh	o may be eligi	ble for the [TRIAL NAM	IE] trial (i.e., [PATIENT
○ Daily					
Weekly					
Monthly					
Every few mon	ths				
 A couple times 	per year or le	ess			
Oo not know					
S5. Which specialty potentially eligible pa		tion would most	t likely be in the	position to recommer	nd or refer this trial to a
 Medical oncol 	ogy				
 Surgical oncol 	logy				
 Radiation once 	ology				
 Gynecologic o 	ncology				
 Pediatric onco 	logy				
○ [VARIABLE]					
Other (please	specify):				
SE Quarall have diffe	cult do vou b	aliave the ITRIA	L NAMEI trial	will be to open at your	oito?
So. Overall, flow dilli	cuit do you b	elleve tile [1 KiA	IL NAME JUIAN	will be to open at your	Site :
Not at all difficult				Very difficult	
0	0	0	0	0	
Opt out of survey					Save and Continue>
				contact the survey administrat	tor

How difficult does (or would) this issue make it to accrue patients to this trial?	Not make it difficult to accrue patients to the trial	Make it somewhat difficult to accrue patients to the trial	Make it yery difficult to accrue patients to the trial
Getting patients referred to the trial	0	0	0
Burden on patient to participate in the trial (e.g., logistics, time)	0	0	0
Patients declining to enroll (e.g., unwilling to randomize, prefer one study arm)	0	0	0
Inclusion/exclusion criteria of the study	0	0	0
Explaining the trial's details to a patient, including consenting	0	0	0
Cost to the patient (e.g., insurance, reimbursement)	0	0	0
Please elaborate – or provide additional reasons – why you believe patients at your site:	this trial might b	e difficult to a	accrue



If user selects "Yes" to QS9, continue below. Otherwise continue HERE.

Mational	Cancer Ins	stitute		U.S. National Institute	es of Health www.cancer.gov
S10. To date, how	many patients i	nas your site ac	crued to the [TF	RIAL NAME] trial?	
(Number of	patients - integ	ers only)			
☐ My site has no	ot opened this	trial.			
S11. How difficult w	vas the [TRIAL	NAME] trial to o	open at your site	9?	
Not at all difficult				Very difficult	
0	0	0	0	0	
Why?					
100					
12. What were the	top reasons fo	or opening the [TRIAL NAME] to	rial at your site? [Selec	et up to 3.]
- Availability of	fatudu da ia/a)				
 Availability of Ease in accru 					
	eimbursable e	xpenses			
Few competi	ng trials for this	cancer			
The state of the s	The state of the s	ologist(s) in the			
		.g., logistics, co			
				rdination, have equipr	nent needed)
Scientifically	the state of the s				
Fills unmet n	eed for our cur	rent patient pop	ulation		
Other:					
Opt out of survey					Save and Continue>
					AND DESCRIPTION OF THE PARTY OF

Nationa	Cancer Institute	U.S. National Institutes of Health www.cancer.gov
S13. Do you have a	any final comments about the [TRIAL N	AME] trial that you would like to share?
Opt out of survey		Submit Survey>
	If you experience any technical difficulties, p at User-Centered Design at survey	lease contact the survey administrator @user-centereddesign.com

Mational Cancer Institute	U.S. National Institutes of Health www.cancer.go
vey Complete	
Thank you for comple	ting this survey!
Your answers have been su	bmitted anonymously.
We appreciate your feedback regal Your comments will help us decide how to move for	
If you would like a summary of the findings after 61164thfirlab@n	
You may now close	e this window.
If you experience any technical difficulties, pli at User-Centered Design at survey	

	National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
S8. Hov NAME]	w many similar trials are open at your site that competrial?	te for the same patient population as the [TRIAL
	Number of similar trials open at y (Integers	
	# competing trials that are sponsored by NCI (includ	ing cooperative group trials)
	# competing trials that are sponsored by pharmaceu	tical/biotech industry
	# competing trials that are investigator initiated trials	from academic medical centers
S9. Has		
Opt out	of survey	Save and Continue>
	If you experience any technical difficulties, ple at User-Centered Design at <u>survey</u> €	

National Cancer Institute S10. Given what you read in the trial summary sheet, how interest your site?			U.S. National Institutes of Health www.cancer.go		
Not at all				Very	
O	0	0	0		
11. What are the t	interesting end	ough	pened the [TR	IAL NAME] trial?	
Not scientifically Does not match Limited interest Too many comp Too great of a b Too difficult to o	v interesting end our patient pop by oncologist(s eeting trials for the urden on patien onduct the study o our site would ccrue patients (ough pulation here his cancer hts (e.g., logistic y (e.g., burden be too great (e e.g., randomiza	cs, cost) on staff, coord	IAL NAME] trial? ination required, equipment needed) ursable expenses) g many to identify one; anticipate high refu	sals)

National	Cancer Institute	U.S. National Institutes of Health www.cancer.gov
S12. Do you have a	any final comments about the [TRIAL NA	ME] trial that you would like to share?
Opt out of survey		Submit Survey>
	If you experience any technical difficulties, ple at User-Centered Design at survey©	ase contact the survey administrator user-centereddesign.com

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Survey Complete	
Thank you for completing this survey!	
Your answers have been submitted anonymously.	
We appreciate your feedback regarding the [TRIAL NAME] trial. Your comments will help us decide how to move forward to address the trial's accrual challenges.	
If you would like a summary of the findings after the survey closes, please send an email to 61164thflrlab@mail.nih.gov	
You may now close this window.	
If you experience any technical difficulties, please at User-Centered Design at survey@us	